Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy

Contemporary Therapeutic Approaches Targeting Bone Complications in Prostate Cancer

(2011) Richard J. Lee et al.   Clinical Genitourinary Cancer

Intermittent hormonal therapy for prostate cancer

(2011) Fernando Calais da Silva   CURRENT OPINION IN UROLOGY

Management of Side Effects of Androgen Deprivation Therapy

(2011) Mathis Grossmann et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

716 PHASE III STUDY OF INTERMITTENT MAB VS CONTINUOS MAB

(2011) Fernando M. Calais da Silva et al.   JOURNAL OF UROLOGY

Toremifene Decreases Vertebral Fractures in Men Younger Than 80 Years Receiving Androgen Deprivation Therapy for Prostate Cancer

(2011) Matthew R. Smith et al.   JOURNAL OF UROLOGY

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

(2011) Matthew R Smith et al.   LANCET

Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials

(2011) Anthony V D'Amico et al.   LANCET ONCOLOGY

The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab

(2011) D. Castellano et al.   ONCOLOGIST

Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer

(2011) Johan F. Langenhuijsen et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?

(2010) Mathis Grossmann et al.   CLINICAL ENDOCRINOLOGY

142 PHASE III STUDY OF INTERMITTENT MONOTHERAPY VERSUS CONTINUOUS COMBINED ANDROGEN DEPRIVATION

(2010) F. Calais Da Silva Junior et al.   EUROPEAN UROLOGY SUPPLEMENTS

Androgen Deprivation Therapy for Prostate Cancer: Recommendations to Improve Patient and Partner Quality of Life

(2010) Stacy Elliott et al.   Journal of Sexual Medicine

Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

(2010) Matthew R. Smith et al.   JOURNAL OF UROLOGY

Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group

(2009) Fernando E.C. Calais da Silva et al.   EUROPEAN UROLOGY

Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics

(2009) Bertrand Tombal et al.   EUROPEAN UROLOGY

Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature

(2009) Per-Anders Abrahamsson   EUROPEAN UROLOGY

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

(2009) Claude C. Schulman   EUROPEAN UROLOGY SUPPLEMENTS

44 INTERMITTENT VERSUS CONTINUOUS MAXIMAL ANDROGEN BLOCKADE IN METASTATIC (D2) PROSTATE CANCER PATIENTS. A RANDOMIZED TRIAL

(2009) N. Mottet et al.   EUROPEAN UROLOGY SUPPLEMENTS

Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

(2009) Matthew R. Smith et al.   JOURNAL OF UROLOGY

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

(2009) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Holistic Approach to Androgen Deprivation Therapy: Treating the Cancer without Hurting the Patient

(2009) Bertrand Tombal   UROLOGIA INTERNATIONALIS

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

(2008) Laurence Klotz et al.   BJU INTERNATIONAL

Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks

(2008) Hendrik Isbarn et al.   EUROPEAN UROLOGY

INTERMITTENT ANDROGEN SUPPRESSION IN PATIENTS WITH ADVANCED PROSTATE CANCER: AN UPDATE OF THE TULP SURVIVAL DATA

(2008) J.F. Langenhuijsen et al.   EUROPEAN UROLOGY SUPPLEMENTS

EVALUATION OF QUALITY OF LIFE, SIDE EFFECTS AND DURATION OF THERAPY IN A PHASE 3 STUDY OF INTERMITTENT MONOTHERAPY VERSUS CONTINUOUS COMBINED ANDROGEN DEPRIVATION

(2008) F.E. Calais Da Silva et al.   EUROPEAN UROLOGY SUPPLEMENTS

QUALITY OF LIFE EFFECTS OF INTERMITTENT AND CONTINUOUS HORMONAL THERAPY BY CYPROTERONE ACETATE (CPA) FOR METASTATIC PROSTATE CANCER

(2008) P.C.M.S. Verhagen et al.   EUROPEAN UROLOGY SUPPLEMENTS

Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?

(2008) Celestia S Higano   Nature clinical practice. Urology

Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro

(2007) H Michael et al.   BRITISH JOURNAL OF PHARMACOLOGY